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BACKGROUND: Melatonin reduces the development of breast cancer interfering with oestrogen-signalling pathways, and also inhibits
aromatase activity and expression. Our objective was to study the promoters through which melatonin modifies aromatase
expression, evaluate the ability of melatonin to regulate cyclooxygenases and assess whether the effects of melatonin are related to its
effects on intracellular cAMP, in MCF-7 cells.
METHODS: Total aromatase mRNA, aromatase mRNA promoter regions and cyclooxygenases mRNA expression were determined by
real-time RT–PCR. PGE2 and cAMP were measured by kits.
RESULTS: Melatonin downregulated the gene expression of the two major specific aromatase promoter regions, pII and pI.3, and also
that of the aromatase promoter region pI.4. Melatonin 1nM was able to counteract the stimulatory effect of tetradecanoyl phorbol
acetate on PGE2 production and inhibit COX-2 and COX-1 mRNA expression. Melatonin 1nM elicited a parallel time-dependent
decrease in both cyclic AMP formation and aromatase mRNA expression.
CONCLUSIONS: This study shows that melatonin inhibits aromatase activity and expression by regulating the gene expression of specific
aromatase promoter regions. A possible mechanism for these effects would be the regulation by melatonin of intracellular cAMP
levels, mediated by an inhibition of cyclooxygenase activity and expression.
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Oestrogens are involved in the growth and differentiation of the
normal mammary gland and have an important role in the genesis
and growth of mammary tumours (Russo and Russo, 1998).
Melatonin, the main hormone secreted by the pineal gland, has
been shown to exert oncostatic properties on hormone-dependent
mammary cancer (Cos and Sa ´nchez-Barcelo ´, 2000a,b; Blask et al,
2002). Evidence from in vivo studies on animal models and in vitro
studies on human breast cancer cell lines support the hypothesis
that melatonin oncostatic effects on hormone-dependent
mammary tumours are mainly dependent on its ability to inter-
act with the oestrogen-signalling pathway (Hill and Blask, 1988;
Cos et al, 2006b, 2008). At the mammary tumour cell level,
melatonin interferes with the oestrogen receptor and counter-
acts the effects of oestrogens, thus behaving as a selective
oestrogen receptor modulator (Blask and Hill, 1986; Hill and
Blask, 1988). Furthermore, melatonin regulates the activity of some
enzymes responsible for the local synthesis of oestrogens in human
breast cancer, thus behaving as a selective oestrogen enzyme
modulator (Cos et al, 2008; Gonza ´lez et al, 2008). Using MCF-7
human breast cancer cells in culture, which express aromatase
(Zhou et al, 1993; Sonne-Hansen and Lykkesfeldt, 2005) and the
membrane-bound Gi protein-coupled receptor (MT1) melatonin
receptor (Ram et al, 1998, 2002), our group has previously shown
that melatonin, at physiological concentrations (1nM), reduces
aromatase activity in these cells, both under basal conditions and
when aromatase activity is stimulated by cAMP or cortisol
(Cos et al, 2005). In addition, we also demonstrated by RT–PCR
that melatonin downregulates aromatase mRNA steady-state levels
in MCF-7 cells (Cos et al, 2005). This modulator effect of melatonin
on the enzyme that controls the conversion from androgenic
precursors to oestrogens has also been described in vivo in rats
bearing DMBA-induced mammary tumours (Cos et al, 2006a). The
binding of melatonin to MT1 receptors has been described as the
first step in the antiaromatase action of melatonin on MCF-7 cells
(Gonza ´lez et al, 2007).
Mammary cancer tissue contains all the enzymes responsible for
the local biosynthesis of oestrogens. One of the two major
pathways involved in the synthesis of oestrogens in breast cancer
cells is the aromatase pathway, which transforms androgens into
oestrogens (Landeghem et al, 1985; Yue et al, 1998; Simpson,
2000). It is well known that aromatase activity and expression is
much higher in breast cancer tissue than in normal mammary
tissue, and this is one of the reasons why oestrogen concentration
in this type of tissue is highly elevated (Landeghem et al, 1985; Yue
et al, 1998). This enzyme complex consists of two components:
aromatase cytochrome P-450 protein and, coupled to it,
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sa ubiquitous flavoprotein, NADPH-cytochrome P-450 reductase
(Conley and Hinshelwood, 2001). The gene coding for the
aromatase protein is the largest of the cytochrome P-450 family.
Because its overall homology to other members of the P-450
superfamily is low, aromatase belongs to a separate gene family
designated CYP19 (Santen and Harvey, 1999). Regulation of
aromatase expression in human tissues is quite complex, involving
alternative promoter sites that provide tissue-specific control
(Bulun et al, 2005; Chen et al, 2009). In normal breast, the
mammary adipose tissue maintains low levels of aromatase
expression almost exclusively through promoter I.4, which is
regulated by the combined action of a glucocorticoid and a
member of the class I cytokine family (interleukin 6, 11). However,
in mammary cancer, both in malignant epithelial cells and
surrounding fibroblasts, the expression of aromatase is increased
by the activation of promoters II and I.3 (Bulun et al, 2005; Chen
et al, 2009). Prostaglandin E2 (PGE2) is an important regulator of
aromatase gene expression through promoters II and I.3 (Bulun
et al, 2005). As it is known (a) that melatonin, through an MT1,
downregulates the forskolin-induced increase of cAMP in MCF-7
cells (Kiefer et al, 2002), and (b) that the activation of the two
major promoters driving aromatase expression in breast cancer is
regulated by cAMP (Bulun et al, 2005; Chen et al, 2009), the
objective of this study was to expand our understanding of
the antiaromatase properties of melatonin and to assess whether
the promoters that drive aromatase expression are regulated by
melatonin and to evaluate the ability of this indolamine to directly
regulate cyclooxygenases (COX) gene expression and activity, as
defined by PGE2 production, in MCF-7 cells. In addition, we
studied whether the effects of melatonin on aromatase expression
are related to the effects of this hormone on intracellular cAMP
concentration.
MATERIALS AND METHODS
Cells and culture conditions
MCF-7 human breast cancer cells were purchased from the
American Tissue Culture Collection (Rockville, MD, USA). They
were maintained as monolayer cultures in 75cm
2 plastic culture
flasks in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-
Aldrich, Madrid, Spain) supplemented with 10% fetal bovine
serum (FBS) (Gibco, France), penicillin (20unitsml
 1) and
streptomycin (20mgml
 1) (Sigma-Aldrich) at 371C in a humid
atmosphere containing 5% CO2. Cells were sub-cultured every 3–4
days by suspension in 5mM Na2-EDTA in PBS (pH 7.4) at 371C for
5min. Before each experiment, stock sub-confluent monolayers
(80%) of MCF-7 cells were incubated with 5mM Na2-EDTA in PBS
(pH 7.4) at 371C for 5min, resuspended in DMEM supplemented
with 5% FBS and passed repeatedly through a 25-G needle to
produce a single cell suspension. Cell number and viability were
determined by staining a small volume of cell suspension with
0.4% trypan blue saline solution and examining the cells in a
haemocytometer.
Measurement of total aromatase mRNA and aromatase
promoter regions pI.3, pII, and pI.4 gene expression
MCF-7 cells were grown in medium with phenol red and
supplemented with 10% FBS. Before each experiment, cells were
transferred to a phenol red-free DMEM medium containing 0.5%
charcoal-stripped FBS and maintained for 3 days. Thereafter,
analysis of total aromatase mRNA and aromatase mRNA promoter
regions pI.3, pII, and pI.4 expression in MCF-7 cells was carried
out by reverse transcription real-time RT–PCR, after an incuba-
tion of MCF-7 cells with either melatonin 1nM (Sigma-Aldrich) or
vehicle for 120min.
Total cellular RNA was purified with the Nucleospin RNA II Kit
(Macherey-Nagel, Du ¨ren, Germany), following the manufacturer’s
instructions. Integrity of RNA was assessed by electrophoresis in
ethidium bromide-stained 1.2% agarose-Tris-borate EDTA gels.
The absorbance ratio A260nm/A280nm was greater than 1.8. For
cDNA synthesis, 1mg of total RNA was denaturated at 651C for
10min and reverse transcribed for 50min at 451C with a cDNA
synthesis kit (Bioline, London, UK) in a final volume of 20ml in the
presence of 500ng of oligo (dT)12–18 primer.
Primers used for the amplification of aromatase and promoter-
specific transcripts of aromatase (Sigma Genosys Ltd., Cambridge,
UK), using the housekeeping gene S14, are listed in Table 1.
The primers were designed so that the coding sequence between
the two PCR primer sites is interrupted by at least one intron
in the gene.
Real-time PCRs were performed in an MX3000 (Stratagene,
La Jolla, CA, USA) using Brilliant SYBR Green PCR Master
Mix (Stratagene), following the manufacturer’s instructions.
Amplifications were performed for 40 cycles using the following
temperature profile: 581C, 60s (annealing); 721C, 30s (extension)
and 951C, 30s (denaturation).
In some experiments, to confirm the relationship between PGE2
and aromatase expression, cells were incubated for 120min with
PGE2 10mM, melatonin 1nM and luzindole 10mM (all from Sigma-
Aldrich) before measuring total aromatase mRNA expression. In
addition, the effects of cAMP-modulating agents (8-Br-cAMP and
RP-cAMP; Sigma-Aldrich) on aromatase mRNA steady-state levels
were determined in cells treated with these agents (1mM) in the
presence or absence of melatonin 1nM.
Assay of COX enzymatic activity and PGE2 measurement
To study COX enzymatic activity, as defined by PGE2 synthesis in
culture media, the experiments were performed in 12-well plates.
MCF-7 cells (150000cells) were added to each well and plates were
maintained overnight in DMEM supplemented with 10% FBS,
penicillin (20unitsml
 1) and streptomycin (20mgml
 1), at 371C,
to allow the cells to adhere to the plates. Cells were then serum
starved in defined media for 24h. Thereafter, the media were
changed for fresh ones supplemented with 100mM sodium
arachidonate (Sigma-Aldrich) and containing tetradecanoyl
phorbol acetate (TPA) 10nM (Sigma-Aldrich), melatonin 1nM or
the diluent of these drugs (ethanol, at a final concentration lower
than 0.0001% per plate). After 5h incubation at 371C, the media
were collected, centrifuged to obtain a cell-free fraction and frozen
Table 1 Primers used for RT–PCR detection of aromatase, aromatase
promoter regions pI.3, pI.4, and pII, cyclooxygenases 1 and 2 and S14
(control)
mRNA Sequence
Aromatase (F) 50–TATTGGAAATGCTGATTGCGG
Aromatase (R) 50-TTGGGCTTGGGGAAATACTCG
pI.3 (F) 50-GGGCTTCCTTGTTTTGACTGTAA
pI.3 (R) 50-AGAGGGGGCAATTTAGAGTCTGTT
pII (F) 50-CTCTGAAGCAACAGGAGCTATAGA
pII (R) 50-CAGGCACGATGCTGGTGATG
pI.4 (F) 50-AACGTGACCAACTGGAGCCTG
pI.4 (R) 50-CATCACCAGCATCGTGCCTG
COX-1 (F) 50-ACCCGCACGGGCTATTCCGGC
COX-1 (R) 50-AGGCGCATGAGCATCTCTCGG
COX-2 (F) 50-ATGTATGAGTGTGGGATTTGA
COX-2 (R) 50-TCCAAAATCCCTTGAAGTGGG
S14 (F) 50-TCACCGCCCTACACATCAAAC
S14 (R) 50-TCCTGCGAGTGCTGTCAGAG
(F) sense forward primer; (R) antisense (reverse) primer.
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sat  701C until assays were performed. PGE2 concentration in the
supernatant of culture media was determined by ELISA (Cayman
Chemical Company, Ann Arbor, MI, USA), according to the
protocol provided by the manufacturer.
Measurement of COX-1 and COX-2 mRNA expression
Analysis of COX-1 and COX-2 mRNA expression in MCF-7 cells
was carried out by reverse transcription real-time RT–PCR after
incubating MCF-7 cells with either melatonin 1nM or vehicle for
120min. Total cellular RNA was purified with the Nucleospin RNA
II Kit (Macherey-Nagel, Du ¨ren, Germany) following the manu-
facturer’s instructions. Integrity of RNA was assessed by electro-
phoresis in ethidium bromide-stained 1.2% agarose-Tris-borate
EDTA gels. The absorbance ratio A260nm/A280nm was greater than
1.8. For cDNA synthesis, 1mg of total RNA was denaturated at 651C
for 10min and was reverse transcribed for 50min at 451C using a
cDNA Synthesis kit (Bioline, London, UK) in a final volume of
20ml in the presence of 500ng of oligo (dT)12–18 primer.
PCR was performed using a set of human COX-1- and COX-2-
specific primers (Sigma Genosys Ltd.) listed in Table 1. The coding
sequence between the two PCR primer sites is interrupted by at
least one intron in the gene. As a control quantification, S14 mRNA
was also carried out by RT–PCR using a set of specific primers
(Table 1).
Real-time PCRs were performed in an MX3000 (Stratagene)
using Brilliant SYBR Green PCR Master Mix (Stratagene) following
the manufacturer’s instructions. Amplifications were performed
for 40 cycles using the following temperature profile: 581C, 60s
(annealing); 721C, 30s (extension); and 951C, 30s (denaturation).
Measurement of cAMP levels
MCF-7 cells were grown in a medium supplemented with 10% FBS
for 3 days in the presence of melatonin 1nM or vehicle. Thereafter,
cAMP was analysed using a commercial kit, the Cyclic AMP [
3H]
Assay System (Amersham Biosciences, Barcelona, Spain).
Statistical analysis
Data are expressed as mean±s.e.m. Differences in aromatase
mRNA promoter regions pI.3, pII, and pI.4, and COX-1 and COX-2
mRNA expression, were analysed by unpaired Student’s t-test.
Comparisons of PGE2 levels and total aromatase mRNA expression
were carried out using one-way analysis of variance, followed by
the Student–Newman–Keuls test. Results were considered as
statistically significant at Po0.05.
RESULTS
Effects of melatonin on aromatase promoter regions pI.3,
pII, and pI.4 expression
To determine the promoters involved in the melatonin control of
aromatase expression, we used competitive RT–PCR to amplify
each of the promoter-specific transcripts from RNA extracted from
MCF-7 cells. As shown in Figure 1, melatonin 1nM exerted a
significant (Po0.001) and potent inhibition in aromatase expres-
sion that is specific to the aromatase promoters II, pI.3, and pI.4.
Effect of melatonin on COX enzymatic activity and
production of PGE2
PGE2 production by MCF-7 cells was measured by ELISA to
determine whether cyclooxygenase enzyme activity was modified
after treating cells with physiological concentrations of melatonin
(1nM). The levels of COX activity in MCF-7 cells were low but
detectable. Tetradecanoyl phorbol acetate (TPA) is an exogenous
natural product showing tumour-promoting activity, which,
through the stimulation of protein kinase C activity, induces
COX enzymatic activity and increases the synthesis of PGE2.
Melatonin 1nM was able to significantly counteract (Po0.001) the
stimulatory effect of TPA on PGE2 production by decreasing the
PGE2 concentration to levels similar to those found in culture
media of control cells (Figure 2).
Effects of melatonin on COX-1 and COX-2 mRNA expression
The levels of COX-1 and COX-2 expression in MCF-7 cells were
studied by real-time RT–PCR. Melatonin at physiological (1nM)
doses significantly (Po0.001) inhibited the expression of COX-2
by as much as 10 times (Figure 3). The COX-1 mRNA expression
was also significantly (Po0.005) reduced by melatonin by as much
as four times (Figure 3).
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Figure 1 RT–PCR analysis of the gene expression of aromatase
promoter regions pI.3, pII, and pI.4 in MCF-7 cells after 120min incubation
with melatonin (1nM) or ethanol (0.001%)(control). Data are expressed as
the percentage of the control group.
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Figure 2 Effects of melatonin (1nM) on COX enzymatic activity as
defined by PGE2 production after tetradecanoyl phorbol acetate (TPA)
stimulation. Data are expressed as a percentage of the control group
(mean±s.e.m.).
Melatonin, aromatase promoters and cyclooxygenases
C Martı ´nez-Campa et al
1615
British Journal of Cancer (2009) 101(9), 1613–1619 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sEffects of melatonin on aromatase mRNA expression
induced by PGE2
Figure 4 shows that 1nM melatonin also significantly (Po0.001)
decreased the aromatase mRNA steady-state levels induced by
PGE2, a well-known inducer of aromatase expression. The addition
of luzindole 10mM, a melatonin receptor antagonist, prevented the
inhibitory effect of melatonin on aromatase mRNA steady-state
levels, thus suggesting a potential involvement of melatonin
receptors in these effects.
Effects of melatonin on aromatase mRNA expression and
intracellular c-AMP levels
Figure 5 shows the correlation between time-course changes in
cAMP and aromatase expression after melatonin treatment. As
observed, melatonin 1nM elicited a parallel time-dependent
decrease in both cyclic AMP formation and aromatase mRNA
expression.
To determine whether the effects of melatonin on aromatase
mRNA steady-state levels were dependent (not only coincident) on
the effects of the hormone on intracellular cAMP, we studied
aromatase mRNA steady-state levels from cells treated with agents
that should mimic (Rp-cAMP) or block (8-Br-cAMP) these effects
of melatonin. Figure 6 shows that melatonin significantly (Po0.05)
inhibited aromatase mRNA steady-state levels similar to Rp-cAMP,
an inhibitor of the activation by cAMP. In contrast, 8-Br-cAMP, a
membrane-permeable cAMP analogue significantly (Po0.05)
increased aromatase mRNA steady-state levels. When cells were
also grown in the presence of 1nM melatonin, the aromatase
mRNA expression was significantly (Po0.05) lower than in those
treated only with 8-Br-cAMP.
DISCUSSION
The relevance of oestrogens in the genesis and progression of
breast cancer is supported by important experimental and epi-
demiological evidence (Russo and Russo, 1998). Ovaries are the
main sites of oestrogen synthesis in premenopausal non-pregnant
women. However, after menopause, local synthesis of oestrogens in
some tissues, including mammary tissue, acquires a special
importance in mammary carcinogenesis (Ackerman et al, 1981;
Pasqualini, 2004; Pasqualini and Chetrite, 2005; Suzuki et al, 2005).
The local synthesis of oestrogens depends on the activity of different
enzyme families (aromatase, sulfatases, etc) to transform androgens
into oestrogens, as well as compounds of weak oestrogenic activity
into more active forms. All these enzymes contribute to the
regulation of the oestrogen availability in breast tumours and in
other kinds of tumours, such as in human endometrial carcinoma
(Pasqualini, 2004; Pasqualini and Chetrite, 2005; Suzuki et al, 2005).
This is the reason why a new therapeutic strategy, based on the
inhibition of oestrogen synthesis (drugs collectively known as
selective oestrogen enzyme modulators), is currently being devel-
oped for breast cancer treatment (Wong and Ellis, 2004).
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Figure 3 Effects of melatonin (1nM) or the diluent (ethanol at 0.0001%
final concentration) on COX-1 and COX-2 mRNA expression. Data are
expressed as a percentage of the control group (mean±s.e.m.).
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especially in hormone-dependent mammary tumours, is well
established (Blask et al, 2002; Cos et al, 2006b, 2008). Melatonin
exerts oncostatic effects on breast cancer by interacting with
oestradiol at the oestrogen receptor level (Cos and Sa ´nchez-
Barcelo ´, 2000a,b; Del Rio et al, 2004; Cos et al, 2006b) and by
regulating the activity and expression of some enzymes respon-
sible for the local synthesis of oestrogens (Cos et al, 2005, 2006b,
2008). As we previously showed that melatonin inhibits aromatase
activity and expression, both in vitro in culture of human breast
cancer cells (Cos et al, 2005) and in vivo in rats bearing DMBA-
induced mammary tumours (Cos et al, 2006a), we wanted to
expand our understanding of the antiaromatase properties of
melatonin; therefore, our objective now was to assess which
promoters of the aromatase gene are modified by melatonin.
Furthermore, as there is an association between high cycloox-
ygenase mRNA expression and upregulation of the gene expres-
sion of the two major specific aromatase promoter regions, pII and
pI.3, in breast tumours (Dı ´az-Cruz et al, 2005; Prosperi and
Robertson, 2006), we were also interested in evaluating the ability
of melatonin to directly regulate cyclooxygenase gene expression
and activity as a possible mechanism for the modulation of the
aromatase enzyme.
In disease-free breast tissue, aromatase is primarily expressed in
adipose stromal fibroblasts by the relatively weak promoter I.4.
However, in breast cancer tissue, aromatase promoters I.3 and II
are activated, leading to a marked increase in aromatase
expression in malignant epithelial cells and adipose fibroblasts.
Both promoters are considered to be the major promoters driving
aromatase expression in breast cancer and surrounding adipose
tissue, accounting for 80–90% of total aromatase expression
(Bulun et al, 2005; Chen et al, 2009). This study shows that
melatonin-dependent regulation of aromatase gene expression
occurs mainly through a downregulation of gene expression of the
specific aromatase promoter regions pII and pI.3 in breast cancer
cells. Aromatase pII was the most abundantly expressed compared
with either pI.3 or pI.4, and melatonin inhibitory action was more
potent on the aromatase promoter region pII. Furthermore,
melatonin also decreased the aromatase promoter region’s pI.4
expression in MCF-7 cells. The switch in the regulatory mechanism
of aromatase expression from normal breast tissue to cancerous
tissue has been extensively investigated, and it has been described
that promoters II and I.3 are both regulated by cAMP and factors
that regulate cAMP pathways (Bulun et al, 2005; Chen et al, 2009).
One factor that has been described to regulate the activity of the
aromatase enzyme through the activation of promoter II of the
aromatase gene is the bioactive lipid prostaglandin E2 (Dı ´az-Cruz
et al, 2005; Prosperi and Robertson, 2006). A model to explain the
interrelationship between aromatase and COX enzymes has been
proposed. High levels of expression of COX enzymes and increased
COX activity result in higher levels of PGE2. Elevated PGE2 levels
increase intracellular cAMP and result in an increased aromatase
expression by the activation of promoters I.3 and II. The levels of
PGE2 in the culture medium of MCF-7 cells were low but
detectable, and TPA, which is an inducer of COX enzymatic
activity through the stimulation of protein kinase C activity,
increased the synthesis of PGE2. Melatonin 1nM was able to
counteract significantly the stimulatory effect of TPA on PGE2
production, by decreasing PGE2 concentration similar to levels
found in culture media of control cells. The formation of
prostaglandins occurs through the activity of cyclooxygenases,
rate-limiting enzymes that catalyse the conversion of arachidonic
acid to prostaglandins. There are two isoforms, COX-1 and COX-2.
COX-1 is constitutively expressed in most tissues and considered
to generate prostaglandins for normal functions (Liu and Rose,
1996). Although COX-1 is present at a constant level in most cells
and tissues, some studies have shown that COX-1 activity and
expression is also elevated in human breast cancer tumours,
prostatic tumours and in squamous cell carcinomas of the
oropharynx, hypopharynx and larynx (Liu and Rose, 1996; Hwang
et al, 1998; Erovic et al, 2008). COX-2 is present in breast cancer
tissue but not in normal breast tissue, and can undergo rapid
induction in response to a variety of stimuli, including mitogens,
hormones, cytokines and growth factors (Dı ´az-Cruz et al, 2005).
Prostaglandins produced by COX-2, predominantly prostaglandin
E2, induce inflammation and are potent mediators of a number of
signal transduction pathways that are implicated in cancer
development. Melatonin at physiological (1nM) doses inhibited
the expression of COX-2 in MCF-7 cells by as much as 10 times
(10% of controls). The expression of COX-1 mRNA expression was
also significantly reduced by melatonin by as much as four times
(20% of controls). This study shows that melatonin decreases COX
enzymatic activity and this inhibitory action begins at the
transcriptional level by inhibiting the expression of COX-1 and,
above all, COX-2. Overexpression of COX-2 has been shown to
have a key effect in inflammatory disorders, tissue injury and
tumourigenesis, and several endogenous molecules and natural
products, such as melatonin, salicylates or polyphenols, have been
reported to inhibit COX-2 expression by targeting the transcrip-
tional activation induced by pro-inflammatory mediators
(Wu, 2005). In particular, melatonin has been shown in a carrageenan-
induced inflammation rat model to protect inflammatory tissue
injury, and its protective effect was reported to be correlated with
the suppression of COX-2 expression and COX-2-derived pros-
taglandins in inflamed tissues (Wu, 2005). Recently, by using
computer graphics applications, it has been described that
melatonin has an excellent steric and electronic effect that is
complementary with COX and, therefore, it seems possible that
melatonin might bind to the active site of COX-1 and COX-2,
modulating the activity of this enzyme (De la Rocha et al, 2007).
Anti-inflammatory actions of melatonin, in which this indolamine
specifically prevents the activation of the COX-2 enzyme, have also
been described in vitro in cultures of C6 glioma cells (Esposito
et al, 2008) and in macrophages (Mayo et al, 2005). Melatonin at
physiological (1nM) doses reduced aromatase mRNA steady-state
levels both under basal conditions and when aromatase mRNA
expression was stimulated by adding PGE2. The inhibitory effect of
melatonin was reverted by luzindole and cells had levels of
aromatase mRNA expression similar to control cells, indicating
that melatonin acts through known melatonin receptor-mediated
mechanisms.
Melatonin, through a membrane-bound Gi protein-coupled
receptor (MT1), downregulates cAMP in different cell types
(Godson and Reppert, 1997; Kiefer et al, 2002). In MCF-7 cells, it
has been shown that melatonin at a nanomolar concentration
reduces the forskolin-induced increase of cAMP (Kiefer et al, 2002)
and, in murine mammary tissue, melatonin decreases cAMP and
increases cGMP in both a dose- and time-dependent manner
(Cardinali et al, 1992). Furthermore, the activation of the two
major promoters driving aromatase expression in breast cancer is
regulated by cAMP and by factors that regulate cAMP levels (Bulun
et al, 2005; Chen et al, 2009). When we compared the time course
of the action of melatonin on cyclic AMP formation with the time
course of melatonin on aromatase mRNA expression, we found
that melatonin 1nM elicited a time-dependent decrease in both
cyclic AMP formation and aromatase mRNA expression. Further-
more, melatonin inhibition of aromatase mRNA expression is
similar to that elicited by Rp-cAMP, an inhibitor of activation by
cAMP, whereas melatonin counteracted the stimulatory effect of an
analogue of cAMP (8-Br-cAMP).
Although promoter I.4 is less important in breast cancer, MCF-7
cells express this promoter, and melatonin 1nM was able to decrease
its expression. Promoter I.4 is regulated by a combined action of a
glucocorticoid and a member of the class I cytokine family
(interleukin 6, 11) (Bulun et al,2 0 0 5 ;C h e net al, 2009). Because
it is known that melatonin represses dexamethasone-induced
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et al, 2005), this melatonin regulation of glucocorticoid receptor
transcriptional activity could be a link between melatonin and
inactivation of aromatase promoter region pI.4 expression.
Taken together, all these results demonstrate that one of the
mechanisms through which melatonin can modulate aromatase
enzyme in breast tumour cells is through its downregulatory action
on the expression of COX enzymes, which decrease the levels of
PGE2. Lower levels of PGE2 decrease intracellular levels of cAMP,
which in turn decrease the activation of promoters I.3 and II and
result in decreased aromatase expression. Lower levels of
aromatase lead to lower levels of oestrogens, resulting in decreased
growth and development of breast tumour.
In conclusion, this study shows that melatonin inhibits
aromatase activity and expression by regulating the gene expres-
sion of specific aromatase promoter regions, and at least one
mechanism through which this could occur is the melatonin
regulation of intracellular cAMP levels, mediated by a modulation
of cyclooxygenase activity and expression induced by melatonin.
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